Insitro, Biotech AI’s quiet Unicorn, Unveils Efforts in ALS, Liver Disease, and Cancer at JPM
Insitro, a leading biotech AI company, steps into the limelight, unveiling groundbreaking initiatives in ALS, liver disease, and cancer at the JPMorgan Healthcare Conference. Despite the buzz around AI technologies, Insitro maintained a low profile. Founded in 2018 by Daphne Koller, a renowned Stanford professor and co-founder of Coursera, the company secured over $643 million in venture capital. Boasting 260 employees and an expansive 107,000-square-foot facility in South San Francisco, Insitro pioneers transformative AI applications in biotech, signaling a significant leap forward in leveraging artificial intelligence for advanced healthcare solutions.
Make faster decisions with community advice
- AI Gets Better At Writing Patient Histories When Physicians Engineer The Prompts
- New Study Evaluates Virtual Reality to Reduce Scanxiety in Brain Tumor Patients
- Revolutionizing Healthcare: Harnessing the Power of IoT Solutions for Improved Patient Outcomes
- Carrum Health Raises $45 Million Series B to Expand Cancer Care Offerings and Launch New Service Lines
- Ethical Guardrails Are Essential To Making Generative AI Work For Healthcare
Deploy this technology today
-
nQ Cortex
Matched with Medical Subject Headings (MeSH): Biomedical Technology, Healthcare IT News: Artificial Intelligence
- NLabviva Platform
- Labviva Platform
- AI Dermatologist Platform
- Armis Platform for Healthcare